Arginine polyesteramide polymer as well as preparation method and application thereof
By developing arginine polyesteramide polymers with biocompatible and biodegradable properties, the problem of bioactive materials being difficult to enter the intervertebral disc during treatment of disc degeneration is solved, and the nucleus is promoted without damaging the intervertebral disc Cell proliferation and tissue regeneration provide new treatments for disc degeneration.
Patent Information
- Application Number
- CN202411130784.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-16
AI Technical Summary
It is difficult for existing bioactive materials to enter the disc tissue without damaging the integrity of the disc when treating disc degeneration, resulting in poor treatment effect.
Developed an arginine-based poly(ester amide)s which are prepared by amidation reaction condensation polymerization, with good biocompatibility and biodegradability, and have positive Charge, which can penetrate the cartilage endplate and enter the intervertebral disc tissue, promotes nucleus pulposus cell proliferation and tissue regeneration by inhibiting the IL-17 signaling pathway.
This polymer can penetrate the cartilage endplate without damaging the intervertebral disc, promotes the proliferation of nucleus pulposus cells and tissue regeneration, and rescues the degeneration of the intervertebral disc, providing a new method and way to treat disc degeneration.
Smart Images

Figure CN118994565A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to an arginine polyester amide polymer and a preparation method and application thereof. Background Art
[0002] The intervertebral disc (IVD) is the load-bearing activity center of the basic functional unit of the spine and has three main components: the nucleus pulposus (NP), the annulus fibrosus (AF) and the cartilage endplates (such as Figure 1 ). The nucleus pulposus is the most central tissue in the IVD structure, mainly composed of type II collagen, and contains a considerable amount of elastin and proteoglycans. The annulus fibrosus is located on the periphery of the NP tissue, and its main function is to provide tough fibrous wrapping and stabilization of the NP tissue. When the AF is intact, the highly hydrated NP tissue can maintain its hydrostatic pressure to maintain the functional integrity of the IVD, which also illustrates the interdependence of the various IVD tissues. The cartilage endplate is composed of hyaline cartilage and is located between the AF and NP, and between the upper and lower vertebrae (Vertebral body, VB) around the IVD. The function of the endplate is to serve as a transitional structure between the NP and the vertebrae to increase mechanical stability. In addition to being the load-bearing structure of the intervertebral disc, the cartilage endplate also manages the nutrient exchange between the intervertebral disc tissue and the outside world. Most of the vascular structures in the IVD are located in the cartilage endplate, and nutrients enter the intervertebral disc through the cartilage endplate. Proteoglycans and collagen are important structural components of the extracellular matrix of the cartilage endplate, and have an important influence on the physiological function of the cartilage endplate. Studies have shown that the proteoglycans carried by the cartilage endplates are negatively charged and control the distribution of charged solutes and the osmotic pressure in the matrix. Therefore, the biochemical properties of the cartilage endplates are crucial for maintaining the integrity of the intervertebral disc, especially the proteoglycans that regulate the transport of solutes. Due to the high concentration of proteoglycans, the intervertebral disc is mainly negatively charged, and small uncharged solutes such as glucose and oxygen can diffuse freely into the disc matrix. Negatively charged molecules such as sulfate and chloride ions can relatively easily pass through the endplates, but have difficulty entering the nucleus pulposus. Cations such as sodium and calcium can be freely exchanged with the nucleus.
[0003] Intervertebral disc degeneration is an independent risk factor for low back pain and is closely related to spinal musculoskeletal diseases. Currently, various traditional conservative treatments and surgical treatments are difficult to fundamentally treat and reverse the intervertebral disc degeneration that has occurred. Tissue engineering based on bioactive materials aims to better target the pathogenesis of intervertebral disc degeneration, maintain the intervertebral disc phenotype, and restore the function of the extracellular matrix, thereby providing functional mechanical support.
[0004] However, due to the complexity of the intervertebral disc tissue structure, the current application of bioactive materials in early mild intervertebral disc degeneration is mainly through direct puncture of the annulus fibrosus and injection into the intervertebral disc. This surgical method will destroy the integrity of the intervertebral disc structure and cause more serious intervertebral disc degeneration.
[0005] Therefore, how to allow biomaterials to enter the intervertebral disc tissue and function to treat intervertebral disc degeneration without damaging the integrity of the intervertebral disc is a key issue that needs to be solved urgently. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides an arginine-based poly(ester amide)s (Arg-PEA), which combines the advantages of polyester and polyamide, has good biocompatibility and biodegradability, and carries a positive charge. The polymer can penetrate the cartilage endplate into the intervertebral disc tissue without damaging the integrity of the intervertebral disc, and play a role in treating intervertebral disc degeneration. The scheme adopted by the present invention is as follows:
[0007] The first aspect of the present invention provides a method for preparing an arginine polyester amide polymer, wherein the preparation method uses a monomer Nx and an arginine monomer Arg-yS to undergo condensation polymerization through an amidation reaction under the catalysis of triethylamine, and the reaction formula is as follows:
[0008]
[0009] Among them, x=2-10, y=2~8.
[0010] In the present invention, different arginine polyester amide polymers can be obtained by taking different values of x and y. For example, when x=8 and y=6, 8A6S is prepared; when x=6 and y=6, 6A6S is prepared; and when x=2 and y=6, 2A6S is prepared.
[0011] In some embodiments of the present invention, the monomer Nx is prepared by the following steps:
[0012] Add triethylamine and p-nitrophenol to acetone and keep the reaction at 0°C using an ice bath. Dilute in cold acetone, then add dropwise to the above cooled solution, stir at 0°C for 2h, and leave overnight at room temperature; the resulting product is precipitated in distilled water, washed thoroughly, recrystallized in 4:1 (v:v) ethyl acetate / DMF, and vacuum dried to constant weight to obtain monomer Nx, the reaction formula is as follows:
[0013]
[0014] In some embodiments of the present invention, the arginine monomer Arg-yS is prepared by the following steps:
[0015] L-arginine and Directly mix, then add toluene and p-toluenesulfonic acid monohydrate; heat the solid-liquid reaction mixture to 120-130°C, then stir and reflux for 16-24 hours, and cool to room temperature; pour out the toluene after precipitation, dissolve the product in 75°C isopropanol under stirring, and then precipitate at 4°C to obtain arginine monomer Arg-yS, the reaction formula is as follows:
[0016]
[0017] The second aspect of the present invention provides an arginine polyester amide polymer prepared by any preparation method described in the first aspect of the present invention.
[0018] The third aspect of the present invention provides use of the arginine polyesteramide polymer described in the second aspect of the present invention in the preparation of a drug for treating diseases related to intervertebral disc degeneration.
[0019] In some embodiments of the present invention, the arginine polyesteramide polymer treats intervertebral disc degeneration-related diseases through at least one of the following functions:
[0020] (1) Alleviate the degeneration reaction of nucleus pulposus cells;
[0021] (2) Restore the physiological functions of degenerated nucleus pulposus cells;
[0022] (3) Promote the proliferation of nucleus pulposus cells;
[0023] (4) Promote the regeneration of nucleus pulposus tissue;
[0024] (5) Promote the repair of nucleus pulposus tissue;
[0025] (6) reduce the gene and protein expression levels of MMP13 and ADAMTS5 in nucleus pulposus cells;
[0026] (7) Increase the expression levels of ACAN, Collagen II and SOX9 genes and proteins in nucleus pulposus cells.
[0027] Furthermore, the arginine polyester amide polymer activates the function by inhibiting the IL-17 signaling pathway.
[0028] Furthermore, the inhibition of activation of the IL-17 signaling pathway refers to reducing the expression levels of IL-17R, TRAF6, Act1 and RELA genes and proteins.
[0029] In the present invention, the drug is injected through the upper and lower vertebrae and can penetrate the cartilage plate into the intervertebral disc tissue.
[0030] The fourth aspect of the present invention provides a drug for treating diseases related to intervertebral disc degeneration, comprising the arginine polyesteramide polymer described in the second aspect of the present invention.
[0031] Beneficial effects of the present invention
[0032] Compared with the prior art, the present invention has the following beneficial effects:
[0033] The arginine polyester amide polymer of the present invention combines the advantages of polyester and polyamide, has good biocompatibility and biodegradability, and is positively charged. By utilizing the positively charged property of the arginine polyester amide polymer and the negatively charged property of the cartilage endplate, the polymer can penetrate the cartilage endplate into the intervertebral disc tissue without damaging the integrity of the intervertebral disc, thereby playing a role in treating intervertebral disc degeneration.
[0034] The arginine polyesteramide polymer of the present invention can promote the proliferation of nucleus pulposus cells and the regeneration of nucleus pulposus tissue by resisting the IL-17 signaling pathway, thereby saving intervertebral disc degeneration, providing a new idea for the design and development of bioactive materials, and also providing a new method and approach for the treatment of early mild intervertebral disc degeneration in tissue engineering. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 A schematic diagram of the intervertebral disc anatomy is shown.
[0036] Figure 2 The preparation methods of monomer I, monomer II (arginine monomer) and arginine polyester amide are shown.
[0037] Figure 3 Shows 1 Characterization results of Arg-6-S and 8A6S by H-NMR and FT-IR.
[0038] Figure 4 A schematic diagram of the application method of arginine polyester amide polymer is shown.
[0039] Figure 5 The penetration test of Arg-PEA with different structures and mass ratios is shown, scale bar: 500 μm.
[0040] Figure 6 Shown is a comparison of cy7 radiation efficiency in the intervertebral disc at different time points for 8A6S.
[0041] Figure 7 The effect of different masses of 8A6S on the activity of rat nucleus pulposus cells is shown.
[0042] Figure 8The effect of different masses of 8A6S on apoptosis of rat nucleus pulposus cells is shown.
[0043] Fig. 9 The toxicity of 8A6S of different masses to rat nucleus pulposus cells is shown, scale bar: 100 μm.
[0044] Fig.10 The expression levels of genes and proteins related to nucleus pulposus cell degeneration after 8A6S treatment are shown.
[0045] Fig.11 The expression levels of genes related to nucleus pulposus cell degeneration after 8A6S treatment are shown, scale bar: 100 μm, 50 μm (magnification).
[0046] Fig.12 Schematic diagram of the rat intervertebral disc compression degeneration model is shown, A: sham operation group, B: operation group.
[0047] Fig.13 The in vivo experimental procedure in rats is shown.
[0048] Fig.14 The imaging and statistical results of rat intervertebral discs at different time points are shown.
[0049] Fig.15 Pathological tissue sections of rat intervertebral discs at different time points are shown, scale bar: 400 μm.
[0050] Fig.16 Shown are the expressions of degeneration-related proteins in rat intervertebral discs at different time points, scale bar: 500 μm.
[0051] Fig.17 The results of analysis using RNA sequencing are shown.
[0052] Fig.18 The results of detecting the expression levels of genes related to the IL-17 signaling pathway using qPCR are shown.
[0053] Fig.19 The figure shows the expression levels of proteins related to the IL-17 signaling pathway detected by immunofluorescence, scale bar: 100 μm.
[0054] Fig. 20 The results of detecting the expression levels of genes and proteins related to the IL-17 signaling pathway using qPCR and Western Blot are shown. DETAILED DESCRIPTION
[0055] Unless otherwise indicated, implied from the context, or customary in the prior art, all parts and percentages in this application are based on weight, and the tests and characterization methods used are all synchronized with the filing date of this application. Where applicable, the contents of any patent, patent application or disclosure involved in this application are fully incorporated herein by reference, and their equivalent patent families are also introduced as references, especially the definitions of relevant terms in the art disclosed in these documents. If the definition of a specific term disclosed in the prior art is inconsistent with any definition provided in this application, the definition of the term provided in this application shall prevail.
[0056] Numerical ranges in this application are approximate values, so unless otherwise specified, they may include numerical values outside the range. Numerical ranges include all numerical values from the lower limit to the upper limit increased by 1 unit, provided that there is an interval of at least 2 units between any lower value and any higher value. For a range comprising a numerical value less than 1 or a range comprising a fraction greater than 1 (e.g., 1.1, 1.5, etc.), 1 unit is appropriately considered as 0.0001, 0.001, 0.01 or 0.1. For a range comprising a single digit less than 10 (e.g., 1 to 5), 1 unit is generally considered as 0.1. These are only specific examples of what is intended to be expressed, and all possible combinations of numerical values between the lowest and highest values listed are considered to be clearly recorded in this application.
[0057] The terms "comprising", "including", "having" and their derivatives do not exclude the presence of any other components, steps or processes, and are irrelevant to whether these other components, steps or processes are disclosed in this application. To eliminate any doubt, unless explicitly stated, all compositions using the terms "comprising", "including", or "having" in this application may include any additional additives, adjuvants or compounds. On the contrary, except for those necessary for operating performance, the term "essentially consisting of..." excludes any other components, steps or processes from the scope of any description of the term below. The term "consisting of..." does not include any components, steps or processes that are not specifically described or listed. Unless explicitly stated, the term "or" refers to the listed individual members or any combination thereof.
[0058] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.
[0059] Example
[0060] The following examples are used to demonstrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors that can be used to implement the present invention and therefore can be considered as preferred embodiments of the present invention. However, it will be appreciated by those skilled in the art based on this specification that many modifications may be made to the specific embodiments disclosed herein and still achieve the same or similar results without departing from the spirit or scope of the present invention.
[0061] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, and the disclosure and materials cited therein are hereby incorporated by reference.
[0062] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many technical equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the claims.
[0063] The experimental methods in the following examples are all conventional methods unless otherwise specified. The instruments and equipment used in the following examples are all conventional laboratory instruments and equipment unless otherwise specified; the experimental materials used in the following examples are all purchased from conventional biochemical reagent stores unless otherwise specified.
[0064] Example 1 Preparation method of arginine polyester amide polymer
[0065] (1) Synthesis of Monomer I (N8)
[0066] The synthetic route of N8 monomer is as follows:
[0067] Triethylamine (0.32 mol) and p-nitrophenol (0.31 mol) were added to 200 mL of acetone, and the reaction was maintained at 0°C using an ice bath. Sebacyl chloride was diluted in 100 mL of cold acetone, and then added dropwise to the above cooled solution, stirred at 0°C for 2 hours, and allowed to stand overnight at room temperature. The generated p-nitrophenyl sebacate was precipitated in distilled water, washed thoroughly, recrystallized 3 times in ethyl acetate / DMF (4:1, v:v), and vacuum dried to constant weight to obtain monomer N8 with a yield of 95%, which was sealed and stored.
[0068] (2) Synthesis of Monomer II (Arg-6-S)
[0069] The synthetic route of Arg-6-S monomer is as follows:
[0070] L-arginine (0.04 mol) and 1,6-hexanediol (0.02 mol) were directly mixed, followed by the addition of toluene (400 mL) and p-toluenesulfonic acid monohydrate (0.082 mol). The solid-liquid reaction mixture was heated to 130°C and then stirred and refluxed for 24 hours. The reaction mixture (viscous solid) was then cooled to room temperature. After the toluene was precipitated and poured, the product was dissolved in isopropanol at 75°C under stirring, and then precipitated at 4°C. This was repeated 3 times to obtain the monomer Arg-6-S with a yield of 75%, which was sealed and stored. The structure of the purified monomer Arg-6-S was identified by NMR and IR spectra.
[0071] (3) Synthesis of L-arginine-based polyester amide Arg-PEA (8A6S)
[0072] The polyester amide 8A6S based on L-arginine is synthesized by polycondensation reaction of monomers N8 and Arg-6-S under the catalysis of triethylamine. The specific synthesis method is as follows: Take N8 (2mmol) and Arg-6-S (2mmol), dissolve them in anhydrous DMSO (5mL), and fully mix them by vortexing and stirring under heating conditions at 120°C. After fully dissolved, add triethylamine (3mL) dropwise. Stop stirring and keep the mixture at 80°C overnight. Add the mixed solution dropwise to precooled ethyl acetate for precipitation. After fully stirring, the initial product is obtained, washed with methanol 3 times, and vacuum dried at 60°C to constant weight to obtain purified 8A6S with a yield of 25%, which is sealed and stored. The structure of the purified 8A6S is identified by nuclear magnetic resonance and infrared spectroscopy.
[0073] The reaction equations of each step are as follows Figure 2 shown.
[0074] The NMR and IR results of Arg-6-S and 8A6S are as follows Figure 3 As shown, the results show that arginine polyester amide Arg-PEA was successfully prepared by condensation polymerization of monomer N8 and arginine monomer Arg-6-S under the catalysis of triethylamine through amidation reaction.
[0075] Example 2: Cartilage endplate penetration test of arginine polyesteramide 8A6S
[0076] 1.8 Application of A6S
[0077] (1) GFP fluorescent protein was mixed with 2A2S and 8A6S at different ratios (1:100 and 1:200), and GFP was mixed with PBS as a blank control. Each mixture was mixed by vortexing;
[0078] (2) Surgery was performed on rats anesthetized with ether. A Kirschner wire was used to make holes in the upper and lower vertebrae of the rat's coccygeal Co8 / 9 segment. 50 μL of the mixed solution was injected through the holes using a syringe. Finally, the holes were sealed with bone wax to prevent the polymer from leaking out. Figure 4 );
[0079] (3) Seven days later, the rats were killed by spinal dislocation, and the corresponding vertebral body-intervertebral disc-vertebral body segments were fixed with 4% PFA in the dark overnight;
[0080] (4) Decalcify with EDTA solution in the dark for 14 days.
[0081] 2. Decalcified Cryosections
[0082] (1) The decalcified tissue blocks were transferred to frozen section embedding boxes, embedded with OCT, and placed in a -80°C ultra-low temperature refrigerator for 2 h to allow the OCT to fully solidify;
[0083] (2) Use a cryostat to cut the fixed OCT frozen tissue block into slices with a thickness of 10 μm and attach them to a glass slide;
[0084] (3) Tissue sections should be stored in a -20°C freezer.
[0085] 3. Immunofluorescence of Tissue Sections
[0086] (1) Take out tissue sections stored in a -20°C freezer and thaw at room temperature for 30 min;
[0087] (2) Place the rewarmed slices in a 60°C oven and bake for 15 min;
[0088] (3) Add 4% PFA to completely cover the tissue, fix for 10 min, and then rinse with PBS three times, 5 min each time;
[0089] (4) Gently wipe off the surface liquid and circle the area where the tissue is located with a water-blocking pen;
[0090] (5) Add 0.05% Triton X-100 to completely cover the tissue and permeabilize the tissue. After permeabilization for 10 min, rinse with PBS three times, each time for 5 min.
[0091] (6) Add antigen retrieval solution to completely cover the tissue, incubate at room temperature for 5 min, and then rinse with PBS three times, each time for 5 min;
[0092] (7) Add goat serum to completely cover the tissue and incubate at room temperature for 1 h;
[0093] (8) Remove the goat serum and add a DAPI-containing anti-fluorescence quenching mounting medium to completely cover the tissue. Seal the slide with a coverslip to avoid bubbles. After sealing, place the slide in a humidified box to avoid light.
[0094] (9) The staining results were observed on a laser confocal microscope LSM880 and the tissues were photographed at 10× magnification.
[0095] Immunofluorescence results Figure 5 As shown, when the mass ratio of GFP to 8A6S was 1:200, GFP was significantly aggregated in the intervertebral disc. Since GFP was bound to 2A2S or 8A6S through electrostatic adsorption, it showed that 8A6S could penetrate the cartilage endplate and enter the intervertebral disc. In contrast, the penetration of 2A2S was relatively weak.
[0096] 4. In vivo Imaging System Analysis
[0097] In order to clarify the penetration and duration of 8A6S in rats, the inventors used a small animal in vivo imaging device to further observe the retention time and penetration effect of 8A6S in the rat coccygeal vertebrae at different time points. Specifically:
[0098] (1) After purifying the cy7-NHS dye and BSA protein, they were also combined with 8A6S by electrostatic adsorption at a mass ratio of 1:200 to obtain a Cy7-NHS-BSA+8A6S mixed solution, and a Cy7-NHS-BSA+PBS mixed solution was prepared as a control;
[0099] (2) After the rats were anesthetized, the upper and lower vertebrae of the Co8 / 9 segment of the rat's coccygeal spine were punctured with Kirschner wires, 50 μL of a mixture of Cy7-NHS-BSA+PBS / 8A6S was injected, and the holes were sealed with bone wax;
[0100] (3) Use a small animal in vivo imaging device to capture and record Cy7 fluorescence images of the corresponding segments of the rat's coccygeal vertebrae at corresponding time points.
[0101] (4) The imaging system program was used to adjust the image parameters and perform statistical analysis. Graphpad Prism 9 version was used for statistical calculations. One-way analysis of variance was used to compare whether there were statistical (significant) differences between groups in multiple groups. In this embodiment, a P value > 0.05 was considered to be meaningless (ns), a P value ≤ 0.05 was (*), a P value ≤ 0.01 was (**), and a P value ≤ 0.001 was (***).
[0102] The results are as follows Figure 6As shown, it can be seen that compared with the control group (cy7-NHS-BAS+PBS) injected with cy7 dye only, the group injected with 8A6S (Cy7-NHS-BSA+8A6S) showed no significant changes within 24 hours, and showed a trend of diffusion to the surrounding area on the 3rd day; on the 7th day, some 8A6S had diffused into the intervertebral disc; on the 14th day, the cy7 fluorescence intensity in the intervertebral disc was the strongest, and gradually weakened after 7 days, and the fluorescence dissipated on the 28th day. The average radiation efficiency of cy7 fluorescence in the intervertebral disc was statistically analyzed, and there was no statistical difference in the average radiation efficiency before 3 days. Starting from the 7th day, the average radiation efficiency of the 8A6S group was significantly higher than that of the control group.
[0103] The above results show that 8A6S has strong penetrating power and can penetrate the coccygeal vertebral body and intervertebral disc cartilage endplate of rats and finally enter the intervertebral disc, which also shows that it can be used for in vivo treatment without damaging the intervertebral disc.
[0104] Example 3 Application of arginine polyesteramide polymer in promoting proliferation of rat nucleus pulposus cells and alleviating cell degeneration
[0105] 1. Acquisition and Culture of Primary Rat Nucleus Pulposus Cells
[0106] (1) Healthy adult male Sprague Dawley (SD) rats (8 weeks old, weighing 200 g to 250 g) were selected and anesthetized with ether. The rats were killed by spinal dislocation. The tails were cut with rongeurs, the skin was peeled off and immersed in 0.1% PVP-I disinfectant for 10 minutes, and then transferred to a biosafety cabinet covered with sterile towels.
[0107] (2) Wear surgical gloves and strictly follow the principle of sterility. All operating instruments such as ophthalmic scissors, straight forceps, curved forceps, and hemostatic forceps must be sterilized and dried in advance before use;
[0108] (3) Take out the rat tail soaked in 0.1% PVP-I disinfectant, soak it in PBS to remove excess disinfectant, and pierce the annulus fibrosus with a surgical blade. The jelly-like nucleus pulposus tissue can be observed to pop out of the intervertebral disc. Transfer the tissue into a 6 mm culture dish filled with PBS; about 8 to 10 segments of nucleus pulposus tissue can be obtained from each rat tail;
[0109] (4) Transfer the PBS containing the nucleus pulposus tissue into a 15 ml centrifuge tube;
[0110] (5) Centrifugation, set the program at room temperature, 1000 rpm, 5 min, remove the supernatant, and repeat twice;
[0111] (6) Estimate the total volume of tissue and add an equal volume of sterile 0.2% type II collagenase solution;
[0112] (7) Transfer to a constant temperature shaking box for digestion, set the program at 37°C, 180 rpm, 30 min;
[0113] (8) Remove the centrifuge tube and observe the degree of tissue digestion. If there are too many tissue clumps, the digestion time can be appropriately extended;
[0114] (9) Add an equal volume of DMEM / F12 complete medium to terminate digestion;
[0115] (10) further remove undigested tissue residues through a 70 μm filter;
[0116] (11) Centrifugation, set the program at room temperature, 1300 rpm, 5 min, and remove the supernatant;
[0117] (12) Take 5 mL of DMEM / F12 complete medium to resuspend the tissue / cell pellet and count the single cells using a cell counting plate. 5 pc / mL were transferred into T25 culture flasks;
[0118] (13) Place the culture flask in a 37°C, 5% CO 2 Cultivate in a constant temperature incubator;
[0119] (14) After 3 to 5 days, the medium was changed for the first time after cells were observed to be attached and growing under a microscope, and then the medium was changed every 2 to 3 days;
[0120] (15) When the cells reached 80-90% confluence, 0.25% EDTA-containing trypsin was added to digest the cells, and the cells were subcultured into T75 culture flasks at passages 1 to 3. The 4th to 7th passages of cells were used for experiments.
[0121] 2. Cryopreservation of primary rat nucleus pulposus cells
[0122] When the cells in the logarithmic growth phase in the T75 culture flask reach 80-90% confluence, some of them are frozen for seed preservation. The specific steps are as follows:
[0123] (1) Remove the old culture medium and add 2 mL of PBS to wash once;
[0124] (2) Add 1 mL of 0.25% EDTA-containing trypsin and place in a 37°C cell culture incubator for digestion for 1 min. After most cells have fallen off the wall under an optical microscope, add 2 mL of DMEM / F12 complete medium to terminate digestion;
[0125] (3) Transfer the cell suspension to a centrifuge tube, mix well by pipetting, take 10 μL of the cell suspension, and count single cells using a cell counting plate;
[0126] (4) Centrifugation (4°C, 1000 rpm, 5 min) and remove the supernatant;
[0127] (5) According to 1.0×10 6 / mL cell freezing solution, add appropriate amount of cell freezing solution to resuspend, then transfer to cell freezing tube and mark it;
[0128] (6) Place the cryotube in a programmed cooling box and place it in a -80°C ultra-low temperature freezer overnight;
[0129] (7) The next day, transfer the cells to a liquid nitrogen bottle for cryopreservation.
[0130] 3. Recovery of Primary Rat Nucleus Pulposus Cells
[0131] (1) Take out the cryovial from liquid nitrogen, place it in a 37°C constant temperature water bath, allow it to melt quickly, and then transfer it to a 15 mL centrifuge tube;
[0132] (2) Add 3 volumes of preheated DMEM / F12 medium to the centrifuge tube as a buffer;
[0133] (3) Centrifugation (room temperature, 1000 rpm, 5 min) to remove the supernatant;
[0134] (4) Add pre-warmed DMEM / F12 complete medium to resuspend the cell pellet;
[0135] (5) Inoculate the cells into appropriate culture flasks according to the cell number;
[0136] (6) Place the culture flask at 37°C and 5% CO 2 Culture in a cell culture incubator.
[0137] 4. Treatment of Rat Nucleus Pulposus Cells
[0138] (1) Rat nucleus pulposus cells (RNPC) of passage 3 to 6 were passaged and the cell suspension was inoculated into a well plate;
[0139] (2) After the cells adhered, different amounts of 8A6S were added and incubated for 24 h;
[0140] (3) After the cells adhered, 175 μM 3% hydrogen peroxide solution in complete medium was added. After incubation for 24 h, the original medium was removed, the cells were washed once with PBS, and 200 μg / mL 8A6S solution in complete medium was added and incubated for 24 h.
[0141] 5.8 Biocompatibility testing of A6S
[0142] In order to verify the effect of 8A6S on normal RNPC, the inventors added different masses of 8A6S into primary RNPC, and used CCK-8 solution, Annexin V / PI and Calcein AM / PI to detect the changes in RNPC cell activity, apoptosis and toxicity, respectively.
[0143] 5.1 CCK-8 cell activity assay
[0144] (1) After the RNPCs were treated in the 96-well plate, the original culture medium was removed and washed once with PBS. Then, 10 μL of CCK-8 solution was added to each well to avoid bubbles.
[0145] (2) Setting up blank control: Add corresponding amount of complete culture medium and CCK-8 solution to the wells without cells;
[0146] (3) Incubate in a cell culture incubator for 1 to 4 hours, measure the absorbance at 450 nm using a microplate reader every hour, and continue the experiment at a time point when the absorbance range is appropriate;
[0147] (4) The data were statistically analyzed and the cell survival rate was calculated as (OD value of the experimental group - OD value of the blank group) / (OD value of the control group - OD value of the blank group).
[0148] The results of CCK-8 cell activity assay are as follows Figure 7 As shown, it can be seen that 8A6S can promote the proliferation of RNPC, and the promotion effect is most obvious when 300 μg / mL of 8A6S is added.
[0149] 5.2 Annexin V / PI cell apoptosis detection
[0150] (1) After the RNPCs were treated in the 12-well plate, the original culture medium was removed, and after washing once with PBS, an appropriate amount of trypsin cell digestion solution was added to digest the cells. Be careful to avoid over-digestion of the cells. Gently blow and shake to remove the cells;
[0151] (2) After neutralization and digestion, the suspended cells were transferred to a 1.5 mL EP tube, centrifuged (room temperature, 1000 rpm, 5 min), the supernatant was discarded, and washed three times with PBS;
[0152] (3) Add 195 μL Annexin V-FITC binding solution to resuspend the cells; add 5 μL Annexin V-FITC and 10 μL propidium iodide staining solution, mix gently, and incubate at room temperature in the dark for 10 min;
[0153] (4) Immediate flow cytometry detection: Annexin V-FITC is green fluorescence and propidium iodide (PI) is red fluorescence.
[0154] Annexin V / PI apoptosis assay results Figure 8 As shown, it can be seen that 8A6S has no obvious effect on the apoptosis of RNPC.
[0155] 5.3 Calcein AM / PI cell live / death assay
[0156] (1) Remove the original culture medium from the treated RNPCs in the 24-well plate and wash once with PBS;
[0157] (2) Add 500 μL of Calcein AM detection buffer, 0.5 μL of Calcein AM and PI to each well and incubate at 37°C in the dark for 30 min;
[0158] (3) After the incubation, the inverted fluorescence microscope DMI8 was used to record the images (Calcein AM is green fluorescence, Ex / Em=494 / 517 nm; PI is red fluorescence, Ex / Em=535 / 617 nm).
[0159] Calcein AM / PI cytotoxicity test results are as follows Fig. 9 As shown, it can be seen that 8A6S has no obvious effect on the cell death of RNPC below 200 μg.
[0160] The above results showed that 8A6S had good biocompatibility and could promote the proliferation of RNPC. It had no significant effect on the cell death of RNPC below 200 μg. Therefore, 8A6S with a mass of 200 μg was selected for subsequent experiments.
[0161] The rescue effect of 6.8A6S on the degeneration of rat nucleus pulposus cells
[0162] The gene and protein expression levels of aggrecan (ACAN), type II collagen (Collagen II) and SOX9 decreased with the increase of nucleus pulposus degeneration, while the gene and protein expression levels of matrix metalloproteinase-13 (MMP13) and aggrecanase-5 (ADAMTS5) were inversely correlated with nucleus pulposus degeneration.
[0163] In order to clarify whether 8A6S can restore the physiological function of degenerated rat nucleus pulposus cells, the inventors detected the cell morphology, gene levels or protein levels of Aggrecan, Collagen II, SOX9, MMP13 and ADAMTS5 of rat nucleus pulposus cells after hydrogen peroxide stimulation and 8A6S treatment by real-time fluorescence quantitative PCR, immunoblotting experiments and immunofluorescence.
[0164] (1) Real-time fluorescence quantitative PCR
[0165] RNA of RNPC was extracted using the TRIzol method, and cDNA was synthesized on a T100 Themal Cycler using PrimeScript RT Reagent Kit (Takara).
[0166] Using PowerUp TM SYBR TM Real-time fluorescence quantitative PCR was performed using CFX96 Real-Time System and repeated three times in three independent experiments. -ΔΔCt Method determination.
[0167] The primer and probe sequences of each gene are shown in Table 1:
[0168] Table 1 Primer probe sequence information
[0169]
[0170] The qRT-PCR reaction system was as follows: 2×PowerUp SYBR Green Master Mix 5 μL; upstream primer 0.4 μL; downstream primer 0.4 μL; diluted cDNA template 0.8 μL, ddH 2 O to make up to 10 μL. The reaction conditions are shown in Table 2:
[0171] Table 2qRT-PCR reaction procedure
[0172]
[0173] The CT value of each sample was recorded, and GAPDH was used as the internal reference for mRNA and lncRNA expression. -ΔΔCt The relative expression level was calculated by the method, and the experiment was repeated 3 times.
[0174] (2) Immunoblotting
[0175] The total cell protein was obtained by RIPA lysis method, and the protein concentration was determined by BCA method. After adding protein sample and 5× loading buffer in a ratio of protein sample: loading buffer = 1:4, the mixture was boiled in a 100℃ metal bath for 10 minutes to denature the protein. After that, the protein was placed on ice for standby use or stored in a -20℃ low-temperature refrigerator. The samples were then subjected to protein immunoblotting experiments, and the expression levels of ACAN (proteintech, 13880-1-AP), SOX9, COL2a1 (thermo, PA1-26206), MMP13 (absin, abs154975) and ADAMTS5 (absin, abs124645) proteins were detected using specific antibodies, and GAPDH was used as an internal reference.
[0176] (3) Cell immunofluorescence
[0177] (1) Remove the original culture medium from the treated RNPCs on the cell slides in the 24-well plate, wash with PBS three times, add 250 μl 4% PFA to fix at room temperature for 10 min, and then rinse with PBS three times, each time for 5 min;
[0178] (2) The cells were permeabilized with 0.05% Triton X-100 in PBS and then rinsed three times with PBS for 5 minutes each time after permeabilization for 10 minutes.
[0179] (3) Add goat serum to completely cover the cells and incubate at room temperature for 1 h;
[0180] (4) Remove the goat serum, add the diluted primary antibody solution according to the ratio in the instruction manual, and incubate in a refrigerator at 4°C for 12-16 h;
[0181] (5) Remove the primary antibody solution and rinse with PBS three times, 5 min each time;
[0182] (6) Add secondary antibody solution diluted 1:500 and incubate at room temperature for 1 h;
[0183] (7) Remove the secondary antibody solution and rinse with PBS three times, 5 min each time;
[0184] (8) Take out the cell slides in each well and place them upside down on a glass slide with anti-fluorescence quenching mounting medium containing DAPI to avoid the formation of bubbles, and then place them in a humidified box to avoid light;
[0185] (9) The staining results were observed on a laser confocal microscope LSM880 and the cells were photographed at 10× / 20× magnification.
[0186] qPCR and Western Blot results are as follows Fig.10As shown in the figure, compared with normal rat nucleus pulposus cells, the gene and protein expression levels of Aggrecan and Collagen II in nucleus pulposus cells were significantly decreased after hydrogen peroxide stimulation, while the expression levels of MMP13 and ADAMTS5 were upregulated. After adding 8A6S, the gene and protein expression levels of Aggrecan and Collagen II recovered, while the expression levels of MMP13 and ADAMTS5 were significantly decreased.
[0187] Immunofluorescence results Fig.11 As shown in the figure, after hydrogen peroxide stimulation, the morphology of rat nucleus pulposus cells changed significantly, the cell volume decreased, and the cell number decreased. Secondly, the fluorescence semi-quantitative analysis showed that the expression levels of Aggrecan and Collagen II decreased significantly. After adding 8A6S, the cell morphology gradually returned to normal levels, the cell number increased, and the expression levels of Aggrecan and Collagen II were adjusted back.
[0188] In summary, 8A6S can treat the degeneration of rat nucleus pulposus cells by alleviating the degenerative response of rat nucleus pulposus cells and restoring the physiological function of cells.
[0189] Example 4 Arginine polyesteramide polymer treats intervertebral disc degeneration in rats by promoting nucleus pulposus tissue regeneration
[0190] 1. Construction of rat intervertebral disc compression degeneration model
[0191] (1) Rats were anesthetized by intraperitoneal injection of 10% chloral hydrate;
[0192] (2) Observe and determine the position of the 8th and 10th vertebral discs of the rat's tail vertebrae and mark them. Pay attention to the position of the three blood vessels in the rat's tail and also mark them;
[0193] (3) Use a Kirschner wire to vertically drill holes in the upper and lower vertebrae of the intervertebral disc, taking care to avoid blood vessels;
[0194] (4) Fixation with an Ilizarov-type device with a spring, such as Fig.12 As shown;
[0195] (5) applying an axial force from the distal end to produce a compressive stress of 1.3 MPa, which is close to the instantaneous disc loading force produced by lifting a moderate weight in the human lumbar spine to induce disc degeneration;
[0196] (6) After 7 days, the Ilizarov device was removed and MRI was used to observe the degeneration of the intervertebral disc.
[0197] 2. In vivo animal experiments
[0198] In vivo animal experiment flow chart Fig.13 shown.
[0199] (1) Rats were randomly divided into three groups: normal control group, sham operation control group, and operation group. Rats in the normal group received no special treatment. Rats in the sham operation group were fixed with the device using the above method but without applying pressure. Rats in the operation group were pressurized on the coccygeal intervertebral disc using the above method;
[0200] (2) After 7 days, the three groups of rats were tested by MRI. After statistical data, 3 rats were randomly selected from the surgical group and treated according to the method of Example 2. After decalcification of the intervertebral disc tissue, frozen sections and paraffin sections were performed;
[0201] (3) The remaining rats in the surgery group were injected with 50 μL of 8A6S solution into the vertebrae above and below the cartilage endplates according to the method of Example 2, and then sealed with bone wax. Three rats in the surgery group were injected with PBS as the surgery control group. After 7 days, the experiment was continued according to the method of step (2);
[0202] (4) After 7 days, repeat steps (2) and (3);
[0203] (5) On day 28, after the MRI experiment, all animals were killed, and samples were collected according to step (2) to prepare for subsequent experiments.
[0204] 3. Imaging Data Acquisition
[0205] (1) Magnetic resonance imaging data of all animals were obtained from the 3.0T MRI system SIGNA PIONEER. The Magic sequence was directly processed on the scanning console, and T2WI, T2 mapping and other sequences were automatically generated. The scanning sequence and main parameters are shown in Table 3:
[0206] Table 3 Magic scanning sequence and parameters
[0207]
[0208]
[0209] according to Fig.13 At each time point, the inventors obtained the T2WI and T2 mapping sequence image results of the rat coccygeal vertebrae at each time point, and simultaneously delineated the region of interest ROI in the nucleus pulposus region of the intervertebral disc in the T2 mapping sequence for statistical analysis (e.g. Fig.14 ).
[0210] MRI T2WI results showed that after surgical compression, the height of the rat intervertebral disc decreased significantly and the water content of the nucleus pulposus decreased. After 8A6S treatment, the physiological state of the intervertebral disc gradually recovered over time, the height gradually increased, and the nucleus pulposus gradually recovered. However, the injection of PBS had no significant effect on the degenerated intervertebral disc, proving that the intervertebral disc cannot recover naturally after compression and degeneration.
[0211] The inventors further performed statistical analysis on the T2 mapping values. In order to better reflect the degree of disc degeneration in each rat, the inventors outlined the ROI of the treated disc and the ROI of the normal disc on the same coccyx, and statistically analyzed the ratio of the two. The results showed that the T2 mapping value was significantly reduced after surgery. After the injection of 8A6S, the T2mapping value gradually increased over time and returned to normal levels.
[0212] 3. Staining of Tissue Cryosections
[0213] In order to better reflect the pathophysiological changes of various tissue structures of the intervertebral disc, the inventors cut off the treated rat intervertebral discs, and observed and studied the distribution and changes of various tissues of the intervertebral disc through hematoxylin-eosin, safranin O-fast green staining and alcian blue staining.
[0214] The results are as follows Fig.15 As shown in the figure, compared with the normal group and the sham operation group, the nucleus pulposus of the rat intervertebral disc decreased or even disappeared after pressure application, but the integrity of the annulus fibrosus was not destroyed. After the injection of 8A6S, the annulus fibrosus gradually opened up over time, and the nucleus pulposus cartilage tissue gradually began to regenerate, restoring the normal tissue structure of the intervertebral disc. However, the injection of PBS alone could not restore the degenerated intervertebral disc tissue.
[0215] 5. Immunofluorescence Detection
[0216] In order to further prove the recovery of the physiological function of rat intervertebral disc under the action of 8A6S, the inventors observed the expression of intervertebral disc degeneration related indicators Aggrecan, Collagen II (COL2A1), MMP13, and ADAMTS5 by immunofluorescence method.
[0217] The results are as follows Fig.16 As shown in the figure, compared with the normal group and the sham operation group, the mean fluorescence intensity of Aggrecan and Collagen II in the nucleus pulposus tissue of the rat intervertebral disc decreased significantly after compression surgery, while the expression levels of MMP13 and ADAMTS5 were significantly enhanced. After the injection of 8A6S, the expression levels of Aggrecan and Collagen II gradually increased over time, while the mean fluorescence intensity of MMP13 and ADAMTS5 was the opposite.
[0218] In summary, the results of in vivo animal experiments in rats showed that after 8A6S penetrated the endplate cartilage and entered the intervertebral disc, it promoted the regeneration and repair of the nucleus pulposus tissue and gradually restored the physiological function and tissue structure of the intervertebral disc.
[0219] Example 5 Arginine polyesteramide polymer regulates the proliferation of nucleus pulposus cells and tissues by affecting the IL-17 signaling pathway
[0220] 1.8 The mechanism of A6S in treating nucleus pulposus cell degeneration
[0221] In order to explore the possible mechanism of 8A6S in treating nucleus pulposus cell degeneration, rat nucleus pulposus cells were stimulated with hydrogen peroxide, and then one group was added with PBS and the other group was added with 8A6S, and each group was repeated three times.
[0222] The inventors extracted and sequenced the cell RNA of three groups of rats. By performing bioinformatics analysis on the sequencing results and combining the KEGG enrichment analysis results (such as Fig.17 ), and found that compared with the control group, the downregulated differentially expressed genes were significantly associated with the IL-17 signaling pathway. 4.2.2 Functional verification of the IL-17 signaling pathway
[0223] To verify the role of the IL-17 signaling pathway in the treatment of 8A6S, we detected the expression of the receptor IL-17RC, signal transduction factors Act1 and TRAF6, and downstream factor RELA in the IL-17 signaling pathway by real-time quantitative fluorescence PCR and immunofluorescence.
[0224] 2. Functional verification of IL-17 signaling pathway
[0225] In order to verify the role of the IL-17 signaling pathway in the treatment of 8A6S, the inventors detected the expression of the receptor IL-17RC, signal transduction factors Act1, TRAF6 and downstream acting factor RELA in the IL-17 signaling pathway by real-time quantitative fluorescence PCR and immunofluorescence.
[0226] qPCR results Fig.18 As shown in the results, compared with normal RNPC, the expression levels of IL-17R, TRAF6, Act1 and RELA genes were upregulated after hydrogen peroxide stimulation, and the IL-17 signaling pathway was activated. After 8A6S treatment, the expression of IL-17R, TRAF6, Act1 and RELA genes was reduced, inhibiting the activation of the IL-17 signaling pathway.
[0227] Immunofluorescence images Fig.19As shown in the figure, the results showed that the mean fluorescence intensity of TRAF6, Act1 and IL-17R decreased in RNPC under hydrogen peroxide stimulation. After 8A6S treatment, the expression levels of TRAF6, Act1 and IL-17R increased, proving the inhibitory effect of 8A6S on the IL-17 signaling pathway.
[0228] The above experimental results confirm that the IL-17 signaling pathway plays a key role in the treatment of nucleus pulposus cells, and 8A6S may exert a therapeutic effect on RNPC by inhibiting the IL-17 signaling pathway.
[0229] 3.8A6S treats RNPC by affecting IL-17 signaling pathway
[0230] In order to clarify the key role of IL-17 signaling pathway in 8A6S treatment of nucleus pulposus cell degeneration, the inventors added IL-17A recombinant protein to RNPC stimulated by hydrogen peroxide to activate the IL-17 signaling pathway, and used qPCR and Western Blot to observe the changes in the treatment effect of 8A6S.
[0231] like Fig. 20 As shown, the results showed that compared with normal rat nucleus pulposus cells, the gene and protein expression levels of MMP13 and ADAMTS5 in nucleus pulposus cells were significantly upregulated after hydrogen peroxide stimulation, while the gene expression levels of ACAN and SOX9 decreased. After adding 8A6S alone, the gene and protein expression levels of MMP13 and ADAMTS5 decreased, while the gene expression levels of ACAN and SOX9 increased significantly. However, after adding IL-17A and 8A6S at the same time, the expression levels of MMP13, ADAMTS5, ACAN and SOX9 in nucleus pulposus cells did not change significantly compared with degenerated nucleus pulposus cells.
[0232] The above results indicate that 8A6S promotes cell proliferation and treats degenerated RNPC by inhibiting the IL-17 signaling pathway.
[0233] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A method for preparing an arginine polyester amide polymer, characterized in that: The preparation method uses monomer Nx and arginine monomer Arg-yS to undergo condensation polymerization through an amidation reaction under the catalysis of triethylamine, and the reaction formula is as follows: Among them, x=2, 4, 8, y=2-10.
2. The preparation method according to claim 1, characterized in that: The monomer Nx is prepared by the following steps: Add triethylamine and p-nitrophenol to acetone and keep the reaction at 0°C using an ice bath. Dilute in cold acetone, then add dropwise to the above cooled solution, stir at 0°C for 2h, and leave overnight at room temperature; the resulting product is precipitated in distilled water, washed thoroughly, recrystallized in 4:1 (v:v) ethyl acetate / DMF, and vacuum dried to constant weight to obtain monomer Nx, the reaction formula is as follows:
3. The preparation method according to claim 1, characterized in that: The arginine monomer Arg-yS is prepared by the following steps: L-arginine and Directly mix, then add toluene and p-toluenesulfonic acid monohydrate; heat the solid-liquid reaction mixture to 120-130°C, then stir and reflux for 16-24 hours, and cool to room temperature; pour out the toluene after precipitation, dissolve the product in 75°C isopropanol under stirring, and then precipitate at 4°C to obtain arginine monomer Arg-yS, the reaction formula is as follows:
4. The arginine polyester amide polymer prepared according to the preparation method according to any one of claims 1 to 3.
5. Use of the arginine polyesteramide polymer according to claim 4 in the preparation of a medicament for treating diseases related to intervertebral disc degeneration.
6. The use according to claim 5, characterized in that: The arginine polyester amide polymer treats intervertebral disc degeneration-related diseases through at least one of the following functions: (1) Alleviate the degeneration reaction of nucleus pulposus cells; (2) Restore the physiological functions of degenerated nucleus pulposus cells; (3) Promote the proliferation of nucleus pulposus cells; (4) Promote the regeneration of nucleus pulposus tissue; (5) Promote the repair of nucleus pulposus tissue; (6) reduce the gene and protein expression levels of MMP13 and ADAMTS5 in nucleus pulposus cells; (7) Increase the expression levels of ACAN, Collagen II and SOX9 genes and proteins in nucleus pulposus cells.
7. The use according to claim 6, characterized in that: The arginine polyesteramide polymer functions by inhibiting the activation of the IL-17 signaling pathway.
8. The use according to claim 7, characterized in that: The inhibition of activation of the IL-17 signaling pathway refers to reducing the expression levels of IL-17R, TRAF6, Act1 and RELA genes and proteins.
9. The use according to any one of claims 5 to 8, characterized in that: The drug is injected through the upper and lower vertebrae and is able to penetrate the cartilage plate into the intervertebral disc tissue.
10. A drug for treating diseases related to intervertebral disc degeneration, comprising the arginine polyesteramide polymer according to claim 4.
Citation Information
Patent Citations
Thermoresponsive arginine-based hydrogels as biologic carriers
CN101952348A
Blank PLGA microspheres and preparation method thereof
CN104448356A
Tissue engineered intervertebral disc
CN115279302A
Compositions and methods for promoting the mineralization of biological tissue
US11992517B2
Thermoresponsive arginine-based hydrogels as biologic carriers
US20110008441A1
Cited By
Application of arginine polyesteramide in preparation of medicine for treating dry age-related macular degeneration
CN122351288A
